ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2075

Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients

Michael Gashick1, Todd Wechter2, Tessa Barrett1, Sarah Azarchi2, Stuart Katz3, Andrea L. Neimann4, James Krueger5, Sanja Jelic6, Edward Fisher1, Jose U. Scher7 and Jeffrey S. Berger8, 1Medicine/Cardiology, New York University School of Medicine, New York City, NY, 2Dermatology, New York University School of Medicine, New York City, NY, 3Medicine/Cardiology, New York University School of Medicine, New York, NY, 4Department of Dermatology, New York University School of Medicine, New York, NY, 5The Rockefeller University, New York, NY, 6Medicine/Pulmonary, Columbia University Medical Center, New York City, NY, 7New York University School of Medicine, New York, NY, 8Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, endothelial cells, Inflammation, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory differences between PsO and PsA and how these differences may impart a different CVD risk profile. We directly investigated the vascular endothelium of patients with PsA, PsO and compared to controls to better understand the inflammatory mechanism(s) that predispose psoriatic patients to CVD risk.

Methods:

Twenty patients with psoriatic disease (PD) (mean age 45 years, 55% male, 11.2 ± 19% body surface area (BSA) involvement) were first compared to 10 matched controls. Next, comparisons were made between PsO (n = 14, average age 50 years, 57% male, 11 ± 22% BSA) and active PsA (n = 6, average age 36 years, 50% male, 11 ± 10% BSA, average 2 – 3 tender/swollen joints per individual). To measure vascular endothelial health, venous endothelial cells were collected from the brachial vein using guidewires inserted through an angiocatheter and isolated with CD146-conjugated magnetic beads. Following collection, endothelial mRNA was isolated, converted to cDNA and inflammatory gene profiling performed by RT-qPCR with Taqman probes and primers. Transcripts were chosen based on in vitro gene arrays of human aortic endothelial cells co-stimulated with IL-17 and TNF-α.

Results:

PD patients compared to controls showed a trend towards higher levels of hs-CRP (2.4 ± 4 mg/dl vs. 0.8 ± 2 mg/dl, p = 0.08) with no overall difference noted between PsA and PsO patients (2.8 ± 2 mg/dl vs. 2.7 ± 4 mg/dl, p = 0.24). Transcriptomic profiling of venous endothelial cells comparing PD (PsO and PsA) to controls revealed upregulation of inflammatory cytokine- and chemokine- associated transcripts (lymphotoxin beta [4 – fold], CCL3 [11 – fold], CXCL10 [16 – fold], IL-8 [10 – fold] and IL-1β [4 – fold], P < 0.05 for all) and transcripts related to intracellular adhesion (ICAM1 [2.4 – fold] and inflammation COX-2 [3 – fold], P < 0.05). Increased expression of the chemokine fractalkine (CX3CL1 [2.8 – fold], p < 0.05) and lymphotoxin beta [2 – fold, p = 0.10] were found in patients with active PsA compared to PsO. No differences in CCL3, CXCL10, IL-8, IL-1B, ICAM1 and COX-2 where seen between PsA and PsO patients.

Conclusion:

Endothelial cell pro-inflammatory transcripts are upregulated in patients with active PD compared with controls. Levels of lymphotoxin beta and fractalkine, a chemokine present in inflamed arthritic synovial tissue, are greater in endothelial cells of patients with PsA than PsO. These findings may underlie increased CVD risk in patients with PD and highlight the inflammatory vascular differences between PsO and PsA.


Disclosure: M. Gashick, None; T. Wechter, None; T. Barrett, None; S. Azarchi, None; S. Katz, None; A. L. Neimann, None; J. Krueger, None; S. Jelic, None; E. Fisher, None; J. U. Scher, Janssen, 5,Novartis, 5,UCB, Inc., 5,AbbVie Inc., 5; J. S. Berger, Astra Zeneca, Janssen, 2.

To cite this abstract in AMA style:

Gashick M, Wechter T, Barrett T, Azarchi S, Katz S, Neimann AL, Krueger J, Jelic S, Fisher E, Scher JU, Berger JS. Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/vascular-endothelial-and-inflammatory-differences-in-psoriasis-and-psoriatic-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vascular-endothelial-and-inflammatory-differences-in-psoriasis-and-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology